Migraine treatment with rizatriptan and non-triptan usual care medications: A pharmacy-based study

被引:8
|
作者
Cady, R
Martin, V
Adelman, J
Diamond, M
Sajjan, S
Hu, XH
机构
[1] Merck & Co Inc, Outcomes Res & Management, W Point, PA 19486 USA
[2] Primary Care Network Inc, Headache Care Ctr, Springfield, MO USA
[3] Univ Cincinnati, Div Gen Internal Med, Cincinnati, OH USA
[4] Headache Wellness Ctr, Greensboro, NC USA
[5] Diamond Headache Clin Ltd, Chicago, IL USA
来源
HEADACHE | 2004年 / 44卷 / 09期
关键词
migraine; migraine acute treatment; rizatriptan; non-triptan usual care medications;
D O I
10.1111/j.1526-4610.2004.04172.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effectiveness of rizatriptan to other non-triptan medications in the relief of migraine headache in usual care settings. Background.-Although rizatriptan has been shown to provide effective relief of migraine symptoms in clinical trials, limited data exist directly comparing its effectiveness with non-triptan medications. Methods.-Migraineurs aged 18 to 55 who had been prescribed a new antimigraine drug (rizatriptan 10 mg or a selected class of non-triptan oral medications) were recruited to participate in the study through a national retail pharmacy chain. Participants completed a baseline questionnaire at the enrollment and reported their treatment experiences by filling out the treatment diary after using the newly prescribed medication. The treatment outcomes of patients receiving rizatriptan were compared with those receiving non-triptan medications. Logistic regression analysis was applied to test statistical significance with adjustment for potential confounding factors. Results.-Of the 728 patients who entered the study, 693 (95.2%) completed the treatment diary. Patients treated with rizatriptan (192) and non-triptans (501) reported the following outcomes, respectively-onset of headache relief within 30 minutes post-dose: 25% versus 18%; self-defined significant headache relief within 2 hours post-dose: 71% versus 54%; pain free or mild pain at 2 hours post-dose: 58% versus 47%; completely symptom-free within 2 hours of post-dose: 32% versus 20%; return to usual activities within 2 hours post-dose: 39% versus 35%; and satisfied with treatment: 67% versus 55% (P < .05 in all comparisons with exception of returning to usual activities). Conclusion.-Rizatriptan was significantly more effective than non-triptans in the relief of migraine headaches for patients obtaining prescribed migraine medications from a retail pharmacy. Additional studies at other usual care settings may be needed to confirm the findings.
引用
收藏
页码:900 / 907
页数:8
相关论文
共 50 条
  • [41] Acupuncture, or non-directive counselling versus usual care for the treatment of depression: a pilot study
    Sylvia Schroer
    Hugh MacPherson
    Trials, 10
  • [42] Acupuncture, or non-directive counselling versus usual care for the treatment of depression: a pilot study
    Schroer, Sylvia
    MacPherson, Hugh
    TRIALS, 2009, 10
  • [43] Effectiveness and tolerability of the thyme/ivy herbal fluid extract BNO 1200 for the treatment of acute cough: an observational pharmacy-based study
    Kardos, Peter
    Bittner, Claudia B.
    Seibel, Jan
    Abramov-Sommariva, Dimitri
    Birring, Surinder S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) : 1837 - 1844
  • [44] Visualisation to Support Treatment Adherence in High Blood Pressure (ViSTA-BP): a feasibility study for a community pharmacy-based intervention
    Brown, Sarah
    McRae, David
    Angel, Paul
    Khan, Imtiaz
    McDonnell, Barry
    James, Delyth
    JOURNAL OF HUMAN HYPERTENSION, 2022, 36 (SUPPL 1) : 20 - 21
  • [45] Influence of pre-treatment pain intensity on usage pattern, effectiveness and safety of Aspirin® : Subgroup analysis of six pharmacy-based surveys with 6.985 patients with headache or migraine
    Doerr, Marius
    Gessner, Uwe
    Theurer, Christoph
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [46] Preventive treatment for migraine in primary care, a population-based study in the Netherlands
    Dekker, F.
    Dieleman, J. P.
    Neven, A. Knuistingh
    Ferrari, M. D.
    Assendelft, W. J. J.
    CEPHALALGIA, 2013, 33 (14) : 1170 - 1178
  • [47] Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study
    Joudrey, Paul J.
    Chadi, Nicholas
    Roy, Payel
    Morford, Kenneth L.
    Bach, Paxton
    Kimmel, Simeon
    Wang, Emily A.
    Calcaterra, Susan L.
    DRUG AND ALCOHOL DEPENDENCE, 2020, 211
  • [48] Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care -: A multicentre study in seven European countries
    Bernsten, C
    Björkman, I
    Caramona, M
    Crealey, G
    Frokjær, B
    Grundberger, E
    Gustafsson, T
    Henman, M
    Herborg, H
    Hughes, C
    McElnay, J
    Magner, M
    van Mil, F
    Schaeffer, M
    Silva, S
    Sondergaard, B
    Sturgess, I
    Tromp, D
    Vivero, L
    Winterstein, A
    DRUGS & AGING, 2001, 18 (01) : 63 - 77
  • [49] Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study
    Varnado, Oralee J.
    Vu, Michelle
    Buysman, Erin K.
    Kim, Gilwan
    Allenback, Gayle
    Hoyt, Margaret
    Trenz, Helen
    Cao, Feng
    Viktrup, Lars
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (04) : 635 - 646
  • [50] IMPACT OF A COMMUNITY PHARMACY-BASED INFORMATION PROGRAM ON TYPE 2 DIABETIC PATIENTS' ADHERENCE: IPHODIA, A CLUSTER RANDOMIZED STUDY VS USUAL PRACTICE-12 MONTH FINAL RESULTS
    Michiels, Y.
    Bugnon, O.
    Chicoye, A.
    Verges, B.
    Moisan, C.
    Mechin, H.
    Allaert, F.
    VALUE IN HEALTH, 2017, 20 (09) : A483 - A483